31 May 2018 | News
This collaboration further enhances Syngene's market-leading capabilities in discovery biology
Syngene International, a research company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology company, to access Zumutor's proprietary nave human phage/yeast display library.
This collaboration further enhances Syngene's market-leading capabilities in discovery biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery.
Under the terms of the agreement, Syngene will screen target antigens against Zumutor's proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners.
Kavitha Iyer Rodrigues, Founder-CEO, Zumutor Biologics said, "Zumutor will use its proprietary antibody display platform to enhance Syngene's discovery programmes. Our antibody engineering expertise and experience enables us to optimize any lead to evolve into a best-in-class differentiated molecule".
Commenting on the collaboration, Dr. Manoj Nerurkar, Chief Operating Officer, Syngene International, said, "Syngene has been a pioneer in discovery research and we see Discovery Biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients".